[HTML][HTML] Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic …
A Iorio, S Halimeh, S Holzhauer, N Goldenberg… - Journal of Thrombosis …, 2010 - Elsevier
Background: Different rates of inhibitor development after either plasma‐derived (pdFVIII) or
recombinant (rFVIII) FVIII have been suggested. However, conflicting results are reported in
the literature. Objectives: To systematically review the incidence rates of inhibitor
development in previously untreated patients (PUPs) with hemophilia A treated with either
pdFVIII or rFVIII and to explore the influence of both study and patient characteristics.
Methods: Summary incidence rates (95% confidence interval) from all included studies for …
recombinant (rFVIII) FVIII have been suggested. However, conflicting results are reported in
the literature. Objectives: To systematically review the incidence rates of inhibitor
development in previously untreated patients (PUPs) with hemophilia A treated with either
pdFVIII or rFVIII and to explore the influence of both study and patient characteristics.
Methods: Summary incidence rates (95% confidence interval) from all included studies for …